Heart Disease Outcomes Transplant 
Journal of Cardiothoracic Surgery
FEBRUARY 9, 2024
Adult patients surviving with congenital heart disease (ACHD) is growing. We examine the factors associated with heart transplant outcomes in this challenging population with complex anatomy requiring redo-sur.
Circulation
NOVEMBER 11, 2024
Heart transplant rates were low but increased slightly in 2020 for patients without CHD, with DV and SV CHD patients showing fluctuating rates peaking in 2018 and 2019, then declining in 2020. Cardiogenic shock rates were highest among SV-CHD patients, with significant fluctuations, followed by DV-CHD patients.
Journal of the American Heart Association
DECEMBER 12, 2023
BackgroundScreening for cardiovascular disease is currently recommended before kidney transplantation. Outcomes were degree of coronary heart disease, revascularization rate following screening, major adverse cardiovascular events, and all‐cause death. 10.8]; and HR, 2.1 [95% 3.9]) and all‐cause death (HR, 12.0 [95%
Journal of the American Heart Association
NOVEMBER 28, 2023
BackgroundDespite improvements in survival over time, the mortality rate for infants with single‐ventricle heart disease remains high. Hierarchical logistic regression, adjusted for potential confounding characteristics, was used to determine the association between SES and death or transplant listing during the interstage period.
Circulation: Cardiovascular Interventions
NOVEMBER 6, 2023
Background:Neonates with complex congenital heart disease and pulmonary overcirculation have been historically treated surgically. However, subcohorts may benefit from less invasive procedures. kilograms [IQR, 2.1–3.3])
Circulation: Heart Failure
FEBRUARY 1, 2024
BACKGROUND:In 2018, an algorithm-based allocation system for heart transplantation (HT) was implemented in France. The cumulative incidence of waitlist mortality estimated with competing risk analysis and incidence of transplantation were compared between diagnosis groups. 2.58];P=0.94; congenital heart disease, 1.82 [95% CI, 0.78–4.26];P=0.17).
Circulation
NOVEMBER 11, 2024
End-stage ischemic heart disease necessitates heart transplantation, and emerging cell therapy presents a promising solution to address donor scarcity. Disruption of gut microbiota significantly influences various diseases and treatments, including transplantation.
Expert insights. Personalized for you.
52 
Let's personalize your content